Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of DA-302168S in Healthy Subjects
NCT06534346Phase 1Completed
- Sponsor
- Chengdu Diao Pharmaceutical Group
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA-302168S in obesity and Overweight (2 arms), sponsored by Chengdu Diao Pharmaceutical Group. Primary endpoints: Maximum Plasma Concentration at Day 6, Time to Maximum Plasma Concentration at Day 6 and 1 more. Started Jul 2024; status: completed.
02
Drugs
DA-302168S
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06534346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534346.